Immunogen (IMGN) Misses Q2 EPS by 3c

July 29, 2022 6:34 AM EDT

Immunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.24), $0.03 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $14.2 million versus the consensus estimate of $16.18 million.

GUIDANCE:

Immunogen sees FY2022 revenue of $75-85 million, versus the consensus of $84.7 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings